VRPX - Virpax Pharmaceuticals, Inc.

0.6695
-0.551   -82.226%

Share volume: 2,782,368
Last Updated: 04-03-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.22
-0.55
-0.45%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
16%
Profitability 0%
Dept financing 50%
Liquidity 31%
Performance 20%
Company vs Stock growth
vs
N/A
0.645 0.199
-0.446 -69.21%
+ Add row to compare
Performance
5 Days
0   0%
1 Month
252.55%
3 Months
83.42%
6 Months
39.77%
1 Year
-80.93%
2 Year
-14.10%
Key data
Stock price
$0.67
P/E Ratio 
0.00
DAY RANGE
$0.45 - $1.18
EPS 
-$5.30
52 WEEK RANGE
$0.10 - $4.04
52 WEEK CHANGE
-$81.71
MARKET CAP 
1.616 M
YIELD 
N/A
SHARES OUTSTANDING 
4.888 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-21-2025
NEXT EARNINGS DATE
04-15-2025
BETA 
-0.77
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,139,768
AVERAGE 30 VOLUME 
$6,376,560
Company detail
CEO: Anthony P. Mack
Region: US
Website: virpaxpharma.com
Employees: 7
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Virpax Pharmaceuticals, Inc. develops various drug-delivery systems and drug-releasing technologies. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee. AnQlar, an anti-viral barrier to prevent or reduce the risk of viral infections in humans, including influenza and SARS-CoV-2.

Recent news
loading